| 1234567891011121314151617181920212223242526272829303132333435363738394041424344454647484950515253545556575859606162636465666768697071727374757677787980818283848586878889909192939495969798991001011021031041051061071081091101111121131141151161171181191201211221231241251261271281291301311321331341351361371381391401411421431441451461471481491501511521531541551561571581591601611621631641651661671681691701711721731741751761771781791801811821831841851861871881891901911921931941951961971981992002012022032042052062072082092102112122132142152162172182192202212222232242252262272282292302312322332342352362372382392402412422432442452462472482492502512522532542552562572582592602612622632642652662672682692702712722732742752762772782792802812822832842852862872882892902912922932942952962972982993003013023033043053063073083093103113123133143153163173183193203213223233243253263273283293303313323333343353363373383393403413423433443453463473483493503513523533543553563573583593603613623633643653663673683693703713723733743753763773783793803813823833843853863873883893903913923933943953963973983994004014024034044054064074084094104114124134144154164174184194204214224234244254264274284294304314324334344354364374384394404414424434444454464474484494504514524534544554564574584594604614624634644654664674684694704714724734744754764774784794804814824834844854864874884894904914924934944954964974984995005015025035045055065075085095105115125135145155165175185195205215225235245255265275285295305315325335345355365375385395405415425435445455465475485495505515525535545555565575585595605615625635645655665675685695705715725735745755765775785795805815825835845855865875885895905915925935945955965975985996006016026036046056066076086096106116126136146156166176186196206216226236246256266276286296306316326336346356366376386396406416426436446456466476486496506516526536546556566576586596606616626636646656666676686696706716726736746756766776786796806816826836846856866876886896906916926936946956966976986997007017027037047057067077087097107117127137147157167177187197207217227237247257267277287297307317327337347357367377387397407417427437447457467477487497507517527537547557567577587597607617627637647657667677687697707717727737747757767777787797807817827837847857867877887897907917927937947957967977987998008018028038048058068078088098108118128138148158168178188198208218228238248258268278288298308318328338348358368378388398408418428438448458468478488498508518528538548558568578588598608618628638648658668678688698708718728738748758768778788798808818828838848858868878888898908918928938948958968978988999009019029039049059069079089099109119129139149159169179189199209219229239249259269279289299309319329339349359369379389399409419429439449459469479489499509519529539549559569579589599609619629639649659669679689699709719729739749759769779789799809819829839849859869879889899909919929939949959969979989991000100110021003100410051006100710081009101010111012101310141015101610171018101910201021102210231024102510261027102810291030103110321033103410351036103710381039104010411042104310441045104610471048104910501051105210531054105510561057105810591060106110621063106410651066106710681069107010711072107310741075107610771078107910801081108210831084108510861087108810891090109110921093109410951096109710981099110011011102110311041105110611071108110911101111111211131114111511161117111811191120112111221123112411251126112711281129113011311132113311341135113611371138113911401141114211431144114511461147114811491150115111521153115411551156115711581159116011611162116311641165116611671168116911701171117211731174117511761177117811791180118111821183118411851186118711881189119011911192119311941195119611971198119912001201120212031204120512061207120812091210121112121213121412151216121712181219122012211222122312241225122612271228122912301231123212331234123512361237123812391240124112421243124412451246124712481249125012511252125312541255125612571258125912601261 |
- <!DOCTYPE html>
- <html lang="zh-CN">
- <head>
- <meta charset="UTF-8">
- <meta name="viewport" content="width=device-width, initial-scale=1.0">
- <meta name="description" content="糖尿病的本质是慢性炎症驱动的β细胞凋亡与胰岛素抵抗。肠漏(肠道通透性增加)是全身炎症的主要来源,炎症毒素(IL-1β、NLRP3)直接损伤胰岛β细胞。从炎症根源入手:肠道菌群检测早期识别、修复肠屏障、富氢水抗氧化干预。科学循证。">
- <meta name="keywords" content="2型糖尿病,糖尿病前期,慢性炎症,胰岛β细胞凋亡,肠漏,肠道菌群,IL-1β,NLRP3炎症小体,主动健康,富氢水,胰岛素抵抗,糖尿病逆转">
- <meta property="og:title" content="糖尿病 · 慢性炎症是β细胞的沉默杀手 · 浠艾福">
- <meta property="og:description" content="中国1.4亿糖尿病患者,1.41亿糖尿病前期。β细胞毒素(炎症)刺激胰岛β细胞凋亡 → 胰岛素分泌不足 → 血糖失控。切断炎症来源(肠漏)是主动健康的根源。">
- <meta property="og:type" content="article">
- <title>糖尿病 · 慢性炎症与β细胞健康 · 浠艾福</title>
- <style>
- :root {
- --bg-dark: #1a2e3d;
- --bg-card: #FFFFFF;
- --bg-alt: #f0f7f0;
- --text-primary: #1a2e3d;
- --text-secondary: #4a5568;
- --text-muted: #718096;
- --accent: #27ae60;
- --accent-light: #eafaf1;
- --blue: #2d7d9a;
- --blue-light: #e8f4f8;
- --green: #38a169;
- --green-light: #f0fff4;
- --orange: #dd6b20;
- --orange-light: #fffaf0;
- --purple: #805ad5;
- --purple-light: #faf5ff;
- --teal: #319795;
- --teal-light: #e6fffa;
- --font: system-ui, -apple-system, "PingFang SC", "Microsoft YaHei", "Noto Sans SC", sans-serif;
- --max-width: 1080px;
- --shadow-card: 0 4px 24px rgba(0,0,0,0.08);
- --shadow-hover: 0 8px 40px rgba(0,0,0,0.12);
- --radius: 16px;
- }
- * { margin: 0; padding: 0; box-sizing: border-box; }
- html { scroll-behavior: smooth; }
- body {
- font-family: var(--font);
- font-size: 1rem;
- line-height: 1.8;
- color: var(--text-primary);
- background: #fff;
- -webkit-font-smoothing: antialiased;
- }
- /* HERO */
- .hero {
- position: relative;
- background: linear-gradient(135deg, #1a2e3d 0%, #2d5a5a 100%);
- color: white;
- padding: 6rem 1.5rem 4rem;
- overflow: hidden;
- min-height: 58vh;
- display: flex;
- align-items: center;
- }
- .hero::before {
- content: '';
- position: absolute;
- inset: 0;
- background:
- radial-gradient(circle at 20% 30%, rgba(39,174,96,0.15) 0%, transparent 50%),
- radial-gradient(circle at 80% 70%, rgba(49,130,206,0.1) 0%, transparent 50%);
- }
- .hero-particles {
- position: absolute;
- inset: 0;
- overflow: hidden;
- pointer-events: none;
- }
- .particle {
- position: absolute;
- width: 6px; height: 6px;
- background: rgba(255,255,255,0.12);
- border-radius: 50%;
- animation: float 8s ease-in-out infinite;
- }
- .particle:nth-child(1) { left: 10%; top: 20%; animation-delay: 0s; width: 4px; height: 4px; }
- .particle:nth-child(2) { left: 25%; top: 60%; animation-delay: 1s; width: 8px; height: 8px; opacity: 0.1; }
- .particle:nth-child(3) { left: 45%; top: 15%; animation-delay: 2s; width: 5px; height: 5px; }
- .particle:nth-child(4) { left: 65%; top: 70%; animation-delay: 0.5s; width: 3px; height: 3px; }
- .particle:nth-child(5) { left: 80%; top: 30%; animation-delay: 3s; width: 7px; height: 7px; opacity: 0.08; }
- .particle:nth-child(6) { left: 15%; top: 85%; animation-delay: 1.5s; width: 4px; height: 4px; }
- .particle:nth-child(7) { left: 55%; top: 45%; animation-delay: 2.5s; width: 9px; height: 9px; opacity: 0.12; }
- @keyframes float {
- 0%, 100% { transform: translateY(0) scale(1); opacity: 0.12; }
- 50% { transform: translateY(-30px) scale(1.5); opacity: 0.25; }
- }
- .hero-content {
- position: relative;
- z-index: 1;
- max-width: var(--max-width);
- margin: 0 auto;
- text-align: center;
- width: 100%;
- }
- .hero-badge {
- display: inline-block;
- background: rgba(39,174,96,0.2);
- color: #68d391;
- font-size: 0.75rem;
- font-weight: 600;
- letter-spacing: 0.08em;
- padding: 0.35rem 1rem;
- border-radius: 999px;
- border: 1px solid rgba(39,174,96,0.3);
- margin-bottom: 1.5rem;
- }
- .hero h1 {
- font-size: clamp(2rem, 5vw, 3.2rem);
- font-weight: 800;
- line-height: 1.2;
- margin-bottom: 1rem;
- background: linear-gradient(135deg, #fff 40%, #9ae6b4 100%);
- -webkit-background-clip: text;
- -webkit-text-fill-color: transparent;
- background-clip: text;
- }
- .hero p {
- font-size: clamp(1rem, 2vw, 1.2rem);
- color: rgba(255,255,255,0.8);
- max-width: 700px;
- margin: 0 auto 2rem;
- line-height: 1.7;
- }
- .hero-stats {
- display: flex;
- gap: 1.5rem;
- justify-content: center;
- flex-wrap: wrap;
- margin-top: 2rem;
- }
- .hero-stat {
- background: rgba(255,255,255,0.08);
- backdrop-filter: blur(8px);
- border: 1px solid rgba(255,255,255,0.1);
- border-radius: 12px;
- padding: 1rem 1.5rem;
- text-align: center;
- min-width: 130px;
- }
- .hero-stat .num {
- font-size: 1.75rem;
- font-weight: 800;
- color: #68d391;
- display: block;
- }
- .hero-stat .label {
- font-size: 0.8rem;
- color: rgba(255,255,255,0.6);
- margin-top: 0.2rem;
- }
- /* TOC */
- .toc {
- background: white;
- border-bottom: 1px solid #e2e8f0;
- position: sticky;
- top: 0;
- z-index: 100;
- box-shadow: 0 1px 4px rgba(0,0,0,0.04);
- }
- .toc-inner {
- max-width: var(--max-width);
- margin: 0 auto;
- padding: 0.75rem 1.5rem;
- display: flex;
- gap: 0.25rem;
- overflow-x: auto;
- -webkit-overflow-scrolling: touch;
- }
- .toc-inner a {
- flex-shrink: 0;
- text-decoration: none;
- font-size: 0.85rem;
- color: var(--text-muted);
- padding: 0.4rem 0.8rem;
- border-radius: 6px;
- transition: all 0.2s;
- white-space: nowrap;
- }
- .toc-inner a:hover { background: var(--bg-alt); color: var(--text-primary); }
- .container { max-width: var(--max-width); margin: 0 auto; padding: 0 1.5rem; }
- section { padding: 4rem 0; }
- section.alt { background: var(--bg-alt); }
- h2 {
- font-size: 1.75rem;
- font-weight: 700;
- margin-bottom: 1.5rem;
- line-height: 1.3;
- }
- h2 .emoji { margin-right: 0.5rem; }
- h3 {
- font-size: 1.15rem;
- font-weight: 600;
- margin: 2rem 0 0.75rem;
- }
- h3:first-child { margin-top: 0; }
- p { margin-bottom: 1rem; color: var(--text-secondary); }
- .alt p { color: var(--text-secondary); }
- /* Highlight Box */
- .highlight-box {
- border-radius: var(--radius);
- padding: 1.5rem 2rem;
- margin: 1.5rem 0;
- border-left: 4px solid;
- }
- .highlight-box.green { background: var(--green-light); border-color: var(--green); }
- .highlight-box.blue { background: var(--blue-light); border-color: var(--blue); }
- .highlight-box.orange { background: var(--orange-light); border-color: var(--orange); }
- .highlight-box.purple { background: var(--purple-light); border-color: var(--purple); }
- .highlight-box.teal { background: var(--teal-light); border-color: var(--teal); }
- .highlight-box p:last-child { margin-bottom: 0; }
- /* Citation Card */
- .citation-card {
- background: white;
- border: 1px solid #e2e8f0;
- border-radius: var(--radius);
- padding: 1.25rem 1.5rem;
- box-shadow: var(--shadow-card);
- transition: box-shadow 0.2s;
- margin-bottom: 1rem;
- }
- .citation-card:hover { box-shadow: var(--shadow-hover); }
- .citation-card .source {
- font-size: 0.75rem;
- color: var(--blue);
- font-weight: 600;
- text-transform: uppercase;
- letter-spacing: 0.05em;
- }
- .citation-card .title { font-weight: 600; font-size: 0.95rem; margin: 0.3rem 0 0.4rem; line-height: 1.4; }
- .citation-card .findings { font-size: 0.85rem; color: var(--text-muted); line-height: 1.6; }
- .citation-card .link {
- display: inline-block; margin-top: 0.5rem; font-size: 0.8rem;
- color: var(--blue); text-decoration: none;
- }
- .citation-card .link:hover { text-decoration: underline; }
- /* Data Card */
- .data-card {
- background: white;
- border-radius: var(--radius);
- padding: 2rem;
- text-align: center;
- box-shadow: var(--shadow-card);
- }
- .data-card .big-number {
- font-size: 3rem; font-weight: 800; line-height: 1;
- }
- .data-card .big-number.green { color: var(--green); }
- .data-card .big-number.blue { color: var(--blue); }
- .data-card .big-number.orange { color: var(--orange); }
- .data-card .unit { font-size: 1rem; color: var(--text-muted); font-weight: 400; }
- .data-card .desc { font-size: 0.9rem; color: var(--text-secondary); margin-top: 0.5rem; }
- .data-grid {
- display: grid;
- grid-template-columns: repeat(auto-fit, minmax(220px, 1fr));
- gap: 1.5rem;
- margin: 1.5rem 0;
- }
- /* Two Col Grid */
- .two-col-grid { display: grid; grid-template-columns: 1fr 1fr; gap: 1rem; }
- .two-col-grid-3 { display: grid; grid-template-columns: repeat(3, 1fr); gap: 1rem; }
- /* Tip Card */
- .tip-card {
- background: white;
- border-radius: var(--radius);
- padding: 1.5rem;
- box-shadow: var(--shadow-card);
- border-top: 3px solid;
- }
- .tip-card.green { border-color: var(--green); }
- .tip-card.blue { border-color: var(--blue); }
- .tip-card.orange { border-color: var(--orange); }
- .tip-card.purple { border-color: var(--purple); }
- .tip-card .tip-icon { font-size: 1.75rem; margin-bottom: 0.5rem; }
- .tip-card h4 { font-size: 1rem; font-weight: 600; margin-bottom: 0.4rem; }
- .tip-card p { font-size: 0.85rem; color: var(--text-muted); margin-bottom: 0; }
- .tip-grid { display: grid; grid-template-columns: repeat(auto-fit, minmax(280px, 1fr)); gap: 1rem; }
- /* Infographic */
- .infographic {
- display: grid;
- grid-template-columns: repeat(auto-fit, minmax(160px, 1fr));
- gap: 1rem;
- margin: 1.5rem 0;
- }
- .info-item {
- text-align: center;
- padding: 1.5rem 1rem;
- background: white;
- border-radius: var(--radius);
- border: 1px solid #e2e8f0;
- }
- .info-item .icon { font-size: 2.5rem; margin-bottom: 0.5rem; }
- .info-item h4 { font-size: 0.9rem; font-weight: 600; margin-bottom: 0.3rem; }
- .info-item p { font-size: 0.8rem; color: var(--text-muted); margin: 0; }
- /* Compare Table */
- .compare-table {
- width: 100%;
- border-collapse: collapse;
- margin: 1.5rem 0;
- font-size: 0.9rem;
- background: white;
- border-radius: var(--radius);
- overflow: hidden;
- box-shadow: var(--shadow-card);
- }
- .compare-table th {
- background: var(--bg-dark);
- color: white;
- padding: 0.75rem 1rem;
- text-align: left;
- font-weight: 600;
- }
- .compare-table td { padding: 0.75rem 1rem; border-bottom: 1px solid #e2e8f0; }
- .compare-table tr:last-child td { border-bottom: none; }
- .compare-table .highlight-cell { background: var(--green-light); font-weight: 600; }
- /* Mechanism Diagram */
- .mechanism-diagram {
- margin: 2rem 0;
- text-align: center;
- }
- .mechanism-diagram img {
- max-width: 100%;
- border-radius: var(--radius);
- box-shadow: var(--shadow-card);
- border: 1px solid #e2e8f0;
- }
- .mechanism-diagram .diagram-caption {
- font-size: 0.8rem;
- color: var(--text-muted);
- margin-top: 0.75rem;
- line-height: 1.6;
- text-align: left;
- background: var(--bg-alt);
- border-radius: 8px;
- padding: 0.75rem 1rem;
- }
- .mechanism-diagram .diagram-caption strong { color: var(--accent); }
- /* Screenshot with annotation */
- .screenshot-block {
- margin: 1.5rem 0;
- }
- .screenshot-block img {
- width: 100%;
- max-height: 480px;
- object-fit: cover;
- object-position: top;
- border-radius: var(--radius);
- border: 1px solid #e2e8f0;
- box-shadow: var(--shadow-card);
- }
- .screenshot-block .screenshot-note {
- font-size: 0.78rem;
- color: var(--text-muted);
- margin-top: 0.4rem;
- line-height: 1.6;
- }
- .screenshot-block .screenshot-note a { color: var(--blue); }
- /* Footer replaced by shared js/footer.js */
- /* Ref link icon */
- .ref-link-icon {
- display: inline-flex;
- align-items: center;
- gap: 0.3rem;
- font-size: 0.8rem;
- color: var(--blue);
- text-decoration: none;
- margin-right: 1rem;
- }
- .ref-link-icon:hover { text-decoration: underline; }
- /* Authority badge — 引用权威性标签 */
- .authority-badge {
- display: inline-flex;
- align-items: center;
- gap: 0.35rem;
- font-size: 0.75rem;
- padding: 0.2rem 0.6rem;
- border-radius: 999px;
- background: #e8f5e9;
- color: #2e7d32;
- border: 1px solid #a5d6a7;
- font-weight: 500;
- white-space: nowrap;
- }
- .authority-badge.high { background: #e3f2fd; color: #1565c0; border-color: #90caf9; }
- .authority-badge.medium { background: #fff3e0; color: #e65100; border-color: #ffcc80; }
- .authority-badge.review { background: #f3e5f5; color: #7b1fa2; border-color: #ce93d8; }
- .authority-badge.rct { background: #e8f5e9; color: #2e7d32; border-color: #a5d6a7; }
- .authority-badge.animal { background: #fce4ec; color: #c62828; border-color: #ef9a9a; }
- .authority-badge.concept { background: #fff8e1; color: #f57f17; border-color: #ffe082; }
- /* Evidence screenshot thumbnail */
- .evidence-thumb {
- display: inline-block;
- margin: 0.5rem 0 0.3rem;
- border-radius: 8px;
- overflow: hidden;
- max-width: 100%;
- border: 1px solid #e2e8f0;
- box-shadow: 0 2px 8px rgba(0,0,0,0.06);
- transition: box-shadow 0.2s;
- cursor: zoom-in;
- }
- .evidence-thumb:hover { box-shadow: 0 4px 16px rgba(0,0,0,0.12); }
- .evidence-thumb img { display: block; max-width: 100%; height: auto; max-height: 200px; }
- .evidence-thumb-label {
- display: block;
- font-size: 0.7rem;
- color: #9ca3af;
- text-align: center;
- padding: 0.2rem;
- background: #f9fafb;
- border-top: 1px solid #f3f4f6;
- }
- /* 英文→中文翻译 */
- .translation {
- display: block;
- font-size: 0.82rem;
- color: var(--blue);
- margin-top: 0.2rem;
- padding: 0.3rem 0.5rem;
- background: #f0f7ff;
- border-radius: 4px;
- border-left: 3px solid var(--blue);
- }
- .translation::before {
- content: "📖 中文翻译:";
- font-weight: 600;
- margin-right: 0.3rem;
- }
- /* Citation card enhancement */
- .citation-card {
- position: relative;
- }
- .citation-card .authority-row {
- display: flex;
- flex-wrap: wrap;
- align-items: center;
- gap: 0.5rem;
- margin: 0.5rem 0 0.3rem;
- }
- /* Ref list */
- .ref-list {
- font-size: 0.85rem;
- line-height: 2;
- color: var(--text-muted);
- }
- .ref-list a { color: var(--blue); text-decoration: none; }
- .ref-list a:hover { text-decoration: underline; }
- .ref-list li { margin-bottom: 0.3rem; }
- /* Inline annotated evidence screenshot */
- .evidence-inline {
- margin: 1.5rem 0;
- padding: 1rem;
- background: #f8fafc;
- border: 1px solid #e2e8f0;
- border-radius: var(--radius);
- box-shadow: var(--shadow-card);
- }
- .evidence-inline .evidence-title {
- font-size: 0.9rem;
- font-weight: 600;
- color: var(--text-primary);
- margin-bottom: 0.6rem;
- display: flex;
- align-items: center;
- gap: 0.4rem;
- }
- .evidence-inline .evidence-image-wrap {
- position: relative;
- display: inline-block;
- max-width: 100%;
- border-radius: 8px;
- overflow: hidden;
- border: 1px solid #e2e8f0;
- }
- .evidence-inline .evidence-image-wrap img {
- display: block;
- max-width: 100%;
- height: auto;
- max-height: 220px;
- }
- .evidence-inline .evidence-highlight {
- position: absolute;
- top: 18%;
- left: 4%;
- width: 92%;
- height: 28%;
- border: 3px dashed #e53e3e;
- background: rgba(229, 62, 62, 0.06);
- border-radius: 6px;
- pointer-events: none;
- }
- .evidence-inline .evidence-highlight::after {
- content: "🔍 关键发现";
- position: absolute;
- top: -22px;
- left: 0;
- background: #e53e3e;
- color: white;
- font-size: 0.7rem;
- padding: 0.15rem 0.5rem;
- border-radius: 4px;
- font-weight: 600;
- }
- .evidence-inline .evidence-caption {
- margin-top: 0.75rem;
- font-size: 0.85rem;
- color: var(--text-secondary);
- line-height: 1.6;
- }
- .evidence-inline .evidence-translation {
- margin-top: 0.5rem;
- padding: 0.5rem 0.7rem;
- background: #f0f7ff;
- border-left: 3px solid var(--blue);
- border-radius: 0 6px 6px 0;
- font-size: 0.82rem;
- color: var(--blue);
- }
- .evidence-inline .evidence-meta {
- margin-top: 0.6rem;
- font-size: 0.8rem;
- color: var(--text-muted);
- }
- .evidence-inline .evidence-meta a {
- color: var(--blue);
- text-decoration: none;
- }
- .evidence-inline .evidence-meta a:hover { text-decoration: underline; }
- /* Warning box */
- .warning { background: #fff8e1; border-left: 4px solid #f39c12; padding: 0.8rem 1rem; border-radius: 0 6px 6px 0; margin: 1rem 0; font-size: 0.9rem; }
- /* Responsive */
- @media (max-width: 640px) {
- .hero { padding: 4rem 1rem 3rem; min-height: auto; }
- .hero-stats { gap: 0.75rem; }
- .hero-stat { min-width: 100px; padding: 0.75rem 1rem; }
- .hero-stat .num { font-size: 1.3rem; }
- .data-grid { grid-template-columns: 1fr; }
- .two-col-grid { grid-template-columns: 1fr; }
- .two-col-grid-3 { grid-template-columns: 1fr; }
- .tip-grid { grid-template-columns: 1fr; }
- section { padding: 2.5rem 0; }
- h2 { font-size: 1.4rem; }
- .highlight-box { padding: 1.25rem; }
- .compare-table { font-size: 0.8rem; }
- .compare-table th, .compare-table td { padding: 0.5rem 0.75rem; }
- }
- </style>
- </head>
- <body>
- <!-- HERO -->
- <header class="hero">
- <div class="hero-particles">
- <div class="particle"></div><div class="particle"></div><div class="particle"></div>
- <div class="particle"></div><div class="particle"></div><div class="particle"></div>
- <div class="particle"></div>
- </div>
- <div class="hero-content">
- <div class="hero-badge">🩺 科学循证 · 主动健康</div>
- <h1>糖尿病 · 症-病-因与主动健康干预</h1>
- <p>中国1.4亿糖尿病患者,但2/3浑然不知。糖尿病前期的最佳干预窗口在症状出现之前——慢性炎症,才是真正的敌人。</p>
- <div class="hero-stats">
- <div class="hero-stat"><span class="num">1.40亿</span><span class="label">糖尿病患者</span></div>
- <div class="hero-stat"><span class="num">1.41亿</span><span class="label">糖尿病前期</span></div>
- <div class="hero-stat"><span class="num">12.8%</span><span class="label">成人患病率</span></div>
- <div class="hero-stat"><span class="num">36.5%</span><span class="label">知晓率(偏低)</span></div>
- </div>
- </div>
- </header>
- <!-- NAV -->
- <nav class="nav">
- <div class="nav-inner">
- <a href="../index.html" class="nav-brand">🩺 浠艾福 · 主动健康学院</a>
- <ul class="nav-links">
- <li><a href="#symptoms">症</a></li>
- <li><a href="#disease">病</a></li>
- <li><a href="#causes">因</a></li>
- <li><a href="#proactive">主动健康五步</a></li>
- <li><a href="#citations">参考文献</a></li>
- </ul>
- </div>
- </nav>
- <!-- ══════════════════════════════════════════
- 症 · 症状识别
- ═════════════════════════════════════════ -->
- <section class="section" id="symptoms">
- <div class="container">
- <div class="section-tag">🔍 症 · 症状识别</div>
- <h2 class="section-title">读懂身体的血糖信号——2型糖尿病的早期症状</h2>
- <p class="section-intro">
- 2型糖尿病的典型"三多一少"(多饮、多尿、多食、体重下降)和早期隐匿信号(疲劳、视力模糊、伤口愈合缓慢)——这些症状出现时,说明胰岛β细胞功能已显著下降(通常丢失约50%),病程已进入临床阶段。主动健康的目标不是在症状出现后降糖,而是在β细胞被炎症损伤之前切断炎症来源。糖尿病前期(空腹血糖受损IFG + 糖耐量减低IGT)患者约90%毫无症状——唯一的识别方式是血液检测。
- </p>
- <div class="evidence-box blue" style="margin-top:2rem;">
- <div class="evidence-box-header">
- <span class="evidence-box-title">⚠️ 出现以下症状请立即就医</span>
- </div>
- <p>① 不明原因体重持续下降(>5%/3个月)+口渴多尿 → 高度怀疑糖尿病。</p>
- <p>② 视力在数周到数月内急剧下降 → 需排查糖尿病视网膜病变或高血糖性晶状体水肿。</p>
- <p>③ 下肢溃疡、伤口经久不愈、足部变色/寒凉 → 需评估糖尿病足风险——全球每20秒就有一例因糖尿病导致的截肢。</p>
- <p>④ 恶心呕吐+呼吸困难+呼气有烂苹果味(丙酮味) → 糖尿病酮症酸中毒(DKA),虽然T2DM中少见,但应激状态可诱发,属于急危重症。</p>
- </div>
- <div class="shot-placeholder">
- <div class="shot-icon">📊</div>
- <span>img/ref-screenshots/diabetes_ref1.png</span>
- </div>
- </div>
- </section>
- <!-- ══════════════════════════════════════════
- 病 · 疾病定义与病理
- ══════════════════════════════════════════ -->
- <section class="section section-alt" id="disease">
- <div class="container">
- <div class="section-tag purple">📖 病 · 疾病定义</div>
- <h2 class="section-title">2型糖尿病:核心病理与流行病学</h2>
- <p class="section-intro">
- 2型糖尿病(Type 2 Diabetes Mellitus, T2DM)是一种以<strong>胰岛素抵抗</strong>和<strong>胰岛β细胞功能进行性衰退</strong>为特征的慢性代谢性疾病。它不再被认为是"不治之症"——通过早期识别和科学干预,糖尿病前期可以逆转,部分新诊断T2DM可进入无药缓解状态。
- </p>
- <div class="stat-row">
- <div class="stat-block">
- <span class="number">1.40亿</span>
- <span class="unit">人</span>
- <span class="desc">中国糖尿病患者(IDF Atlas 2024)</span>
- </div>
- <div class="stat-block">
- <span class="number blue">1.41亿</span>
- <span class="unit">人</span>
- <span class="desc">糖尿病前期(成年人)</span>
- </div>
- <div class="stat-block">
- <span class="number teal">12.8%</span>
- <span class="unit">患病率</span>
- <span class="desc">中国成人糖尿病患病率</span>
- </div>
- <div class="stat-block">
- <span class="number orange">35.2%</span>
- <span class="unit">患病率</span>
- <span class="desc">糖尿病前期患病率</span>
- </div>
- </div>
- <p style="color:var(--text-muted);font-size:0.82rem;margin-bottom:1.5rem;">
- 数据来源:IDF Diabetes Atlas 2024 第11版|中国成人糖尿病知晓率仅36.5%,治疗率32.2%,控制率49.2%
- </p>
- <div class="grid-2">
- <div class="card card-accent">
- <span class="card-icon">🧬</span>
- <h3>核心病理:胰岛素抵抗 + β细胞功能衰竭</h3>
- <p><strong>胰岛素抵抗:</strong>肌肉、脂肪、肝脏等外周组织对胰岛素的敏感性下降——胰岛素"打不开门",葡萄糖无法进入细胞利用。肝脏胰岛素抵抗表现为肝糖输出增加(空腹高血糖);肌肉胰岛素抵抗表现为餐后葡萄糖摄取下降(餐后高血糖)。</p>
- <p style="margin-top:0.5rem;"><strong>β细胞功能进行性减退:</strong>在胰岛素抵抗初期,胰岛β细胞代偿性分泌更多胰岛素来维持血糖正常。但随着病程进展,β细胞逐渐"疲劳",分泌能力下降约50%时,血糖开始失控(从糖尿病前期进入临床糖尿病阶段)。</p>
- <p style="margin-top:0.5rem;"><strong>肠道-胰脏-胰岛轴:</strong>肠促胰岛素激素(GLP-1、GIP)在餐后刺激胰岛素分泌,GLP-1还抑制胰高血糖素释放、延缓胃排空、抑制食欲——这些效应在T2DM患者中显著减弱。</p>
- </div>
- <div class="card card-blue">
- <span class="card-icon">📋</span>
- <h3>WHO/ADA诊断标准</h3>
- <p>以下任何一项满足即可诊断T2DM(需二次确认):</p>
- <div class="table-wrap" style="margin-top:0.8rem;">
- <table>
- <tr><th class="blue">诊断指标</th><th class="blue">阈值</th><th class="blue">说明</th></tr>
- <tr><td>空腹血糖(FPG)</td><td><strong>≥7.0 mmol/L</strong></td><td>禁食至少8小时</td></tr>
- <tr><td>糖化血红蛋白(HbA1c)</td><td><strong>≥6.5%</strong></td><td>反映2-3个月平均血糖</td></tr>
- <tr><td>OGTT 2h血糖</td><td><strong>≥11.1 mmol/L</strong></td><td>75g葡萄糖负荷后2小时</td></tr>
- <tr><td>随机血糖+高糖症状</td><td><strong>≥11.1 mmol/L</strong></td><td>伴典型高血糖症状</td></tr>
- </table>
- </div>
- <p style="margin-top:0.5rem;"><strong>糖尿病前期筛查标准:</strong>FPG 5.6-6.9 mmol/L(空腹血糖受损),或OGTT 2h 7.8-11.0 mmol/L(糖耐量减低),或HbA1c 5.7-6.4%。</p>
- </div>
- </div>
- <div class="evidence-box" style="margin:2rem 0;">
- <div class="evidence-box-header">
- <span class="evidence-box-title">📊 代谢记忆(Metabolic Memory)——早期控制决定长期结局</span>
- <span class="ev-tag">RCT证据 · DCCT/EDIC</span>
- <span class="ev-tag blue">UKPDS</span>
- </div>
- <p><strong>DCCT/EDIC研究</strong>(糖尿病控制与并发症试验及后续观察,n=1441,随访30年):T1DM患者早期强化血糖控制(6.5年)后,虽然试验结束后两组HbA1c趋同,但原强化组的心血管事件风险降低约42%,微血管并发症风险降低约57%。</p>
- <p><strong>UKPDS研究</strong>(英国前瞻性糖尿病研究,n=5102,新诊断T2DM,随访20年):早期强化血糖控制组在后续10年随访中,心肌梗死风险降低15%,全因死亡降低13%——即使后期血糖控制趋同,早期获益仍然延续。</p>
- <p style="margin-top:0.5rem;color:var(--text-muted);font-style:italic;">"代谢记忆"效应意味着:越早主动控制血糖,远期获益越大——这是主动健康理念在糖尿病管理中最有力的科学证据。</p>
- </div>
- <h3 style="font-size:1.1rem;font-weight:700;margin:2rem 0 1rem;">⚙️ T2DM并发症:全身性的血管灾难</h3>
- <div class="grid-2">
- <div class="card card-accent">
- <span class="card-icon">❤️</span>
- <h3>大血管并发症(Macrovascular)</h3>
- <p><strong>心血管疾病:</strong>糖尿病患者CVD风险是非糖尿病的2-4倍。约50%的T2DM患者死于心血管病(心梗、心衰)。高血糖加速动脉粥样硬化,叠加胰岛素抵抗诱导的脂质紊乱(小而密LDL-C颗粒增多、HDL-C降低)。</p>
- <p><strong>脑卒中:</strong>糖尿病使脑卒中风险增加1.5-3倍,且卒中后预后更差。</p>
- <p><strong>外周动脉疾病(PAD):</strong>下肢动脉硬化闭塞风险升高,是糖尿病足溃疡的前驱条件。</p>
- </div>
- <div class="card card-blue">
- <span class="card-icon">🔬</span>
- <h3>微血管并发症(Microvascular)</h3>
- <p><strong>糖尿病视网膜病变:</strong>中国T2DM患者中DR患病率约27.9%,增殖性DR约5%。每年眼底筛查可降低失明风险达90%。</p>
- <p><strong>糖尿病肾病:</strong>约20-40%的T2DM合并糖尿病肾病,是中国终末期肾病(ESRD)的主要病因之一。早期表现是微量白蛋白尿,每年筛查尿ACR可提前3-5年发现。</p>
- <p><strong>糖尿病神经病变:</strong>约50%的T2DM患者最终出现周围神经病变,表现为对称性远端麻木、疼痛。自主神经病变可导致心脏自主神经功能异常(增加猝死风险)、胃轻瘫、勃起功能障碍。</p>
- </div>
- </div>
- <div class="quote-block green" style="margin-top:2rem;">
- <p class="quote-text">"糖尿病不是一种独立的疾病,而是一种代谢综合征的冰山一角。它从糖代谢异常出发,逐步侵蚀全身血管、神经和器官。正因如此,主动健康对糖尿病患者的意义远不止降糖——而是对整个代谢系统的综合治理。"</p>
- <span class="quote-source">— 浠艾福 · 主动健康学院 · 五维幸福理念</span>
- </div>
- <div class="shot-placeholder">
- <div class="shot-icon">📊</div>
- <span>img/ref-screenshots/diabetes_ref2.png</span>
- </div>
- </div>
- </section>
- <!-- ══════════════════════════════════════════
- 因 · 发病原因
- ══════════════════════════════════════════ -->
- <section class="section" id="causes">
- <div class="container">
- <div class="section-tag orange">⚡ 因 · 发病原因</div>
- <h2 class="section-title">2型糖尿病的核心病因——可改变因素与遗传背景</h2>
- <p class="section-intro">
- T2DM的发病是遗传易感性与环境因素共同作用的结果。中国糖尿病患病率的快速攀升不能用基因改变来解释(近40年基因池不变),而是<strong>生活方式剧变引爆了遗传风险</strong>。理解病因是为了找到可干预的靶点——大部分T2DM的致病因素是可以改变的。
- </p>
- <div class="evidence-box" style="margin-bottom:2rem;">
- <div class="evidence-box-header">
- <span class="evidence-box-title">📊 可改变风险因素的归因风险</span>
- <span class="ev-tag">流行病学数据</span>
- </div>
- <p>① 超重/肥胖(BMI≥24):人群归因风险(PAR)约45%——最大单一可改变因素。腹型肥胖(腰围男≥90cm/女≥85cm)尤为关键。</p>
- <p>② 饮食因素:高GI/GL饮食 PAR约25%;膳食纤维摄入不足 PAR约15%;红肉/加工肉类摄入过多 PAR约12%。</p>
- <p>③ 缺乏运动:PAR约18%。</p>
- <p>④ 睡眠不足/障碍:睡眠<6h/天,T2DM风险增加约37%。</p>
- <p>⑤ 慢性心理压力:皮质醇升高直接促进胰岛素抵抗。</p>
- <p>⑥ 吸烟:吸烟者T2DM风险增加约37-44%(日本大型队列)。</p>
- </div>
- <div class="grid-2">
- <div>
- <div class="card card-orange" style="margin-bottom:1.25rem;">
- <span class="card-icon">🍚</span>
- <h3>高血糖生成指数(GI)饮食——最快"升糖"路径</h3>
- <p>中国人以精米白面为主食(GI值>80),这是T2DM高发的关键饮食因素。精制碳水化合物迅速分解为葡萄糖,导致餐后血糖骤升→胰岛素大量释放→反复刺激→β细胞疲劳→胰岛素抵抗加剧。</p>
- <p style="margin-top:0.5rem;"><strong>关键数据:</strong>中国每日人均大米摄入>200g。每天用糙米替代白米,T2DM风险降低约36%(山东队列,10年随访,n=20万)。</p>
- <p style="margin-top:0.5rem;"><strong>含糖饮料:</strong>每日饮用1份含糖饮料(约250ml),T2DM风险增加约13%(Meta分析,n>30万)。</p>
- </div>
- <div class="card card-blue" style="margin-bottom:1.25rem;">
- <span class="card-icon">🍔</span>
- <h3>肥胖——胰岛素抵抗的土壤</h3>
- <p>脂肪组织不是被动的能量仓库,而是活跃的内分泌器官。肥胖时,内脏脂肪分泌大量的促炎因子(TNF-α、IL-6、MCP-1)和游离脂肪酸,直接干扰胰岛素信号传导——这是胰岛素抵抗的核心驱动机制。</p>
- <p style="margin-top:0.5rem;"><strong>脂肪分布比体重更重要:</strong>正常体重但腰围超标者("瘦胖子"),T2DM风险同样显著升高。中国人群对腹型肥胖的代谢损伤更敏感——相同BMI,中国人群的T2DM风险高于白种人。</p>
- </div>
- <div class="card card-purple">
- <span class="card-icon">😴</span>
- <h3>睡眠剥夺——被严重低估的风险因素</h3>
- <p>睡眠不足<6小时/天,T2DM风险增加约37%(Meta分析,n>480,000)。机制:睡眠不足激活交感神经系统→皮质醇升高→炎症反应→直接诱导胰岛素抵抗;同时,睡眠剥夺抑制瘦素、增加饥饿素,导致食欲增加、摄食过量。</p>
- <p style="margin-top:0.5rem;"><strong>阻塞性睡眠呼吸暂停(OSA):</strong>中国约50%的T2DM合并OSA。间歇性缺氧通过氧化应激和炎症通路加剧胰岛素抵抗。治疗OSA(CPAP)可改善HbA1c约0.5%。</p>
- </div>
- </div>
- <div>
- <div class="card card-teal" style="margin-bottom:1.25rem;">
- <span class="card-icon">🧬</span>
- <h3>遗传因素——风险背景</h3>
- <p>T2DM遗传力约30-70%。全基因组关联研究(GWAS)已发现超过400个T2DM相关风险位点:</p>
- <ul class="list-styled green" style="margin-top:0.4rem;">
- <li><strong>TCF7L2</strong>:T2DM最强遗传风险基因(风险等位基因使T2DM风险增加1.5倍)。影响Wnt信号通路、GLP-1分泌和β细胞功能。</li>
- <li><strong>KCNJ11</strong>:编码胰岛β细胞的K_ATP通道。功能变异影响胰岛素分泌能力。</li>
- <li><strong>PPARG</strong>:过氧化物酶体增殖物激活受体γ,是噻唑烷二酮类药物靶点,影响胰岛素敏感性。</li>
- <li><strong>FTO</strong>:肥胖相关基因,通过影响BMI间接增加T2DM风险。</li>
- </ul>
- <p style="margin-top:0.5rem;color:var(--text-muted);font-size:0.82rem;">这些基因变异的效应是"聚沙成塔"式的——单个位点效应微弱(OR 1.05-1.3),但多个风险等位基因叠加则显著增加患病风险。</p>
- </div>
- <div class="card card-orange" style="margin-bottom:1.25rem;">
- <span class="card-icon">😰</span>
- <h3>慢性心理压力——皮质醇的代谢伤害</h3>
- <p>慢性压力通过HPA轴激活→皮质醇持续升高→促进肝脏糖异生、抑制外周组织葡萄糖摄取、促进内脏脂肪堆积→直接导致胰岛素抵抗。一项大型荟萃分析(n>20万)发现:工作压力大者T2DM风险增加约40%。</p>
- <p style="margin-top:0.5rem;"><strong>主动应对:</strong>正念冥想可降低皮质醇约15-20%,提升胰岛素敏感性,是主动健康干预中被低估的手段。</p>
- </div>
- <div class="card card-accent">
- <span class="card-icon">🦠</span>
- <h3>肠道菌群——肠-胰轴与代谢决定</h3>
- <p>人体肠道菌群携带330万基因,其组成与T2DM风险的关联越来越受到关注。肠道菌群通过多条代谢通路影响糖代谢:</p>
- <p><strong>TMAO通路:</strong>红肉中的肉碱和胆碱→肠道菌群产TMA→肝脏FMO3氧化为TMAO→TMAO通过抑制胰岛素信号传导和促进炎症反应加重胰岛素抵抗。高TMAO水平人群T2DM风险增加约54%。</p>
- <p><strong>SCFAs保护通路:</strong>膳食纤维→菌群发酵产生乙酸、丙酸、丁酸→激活GPR41/43→增加GLP-1、PYY分泌→改善胰岛素敏感性。丁酸还直接保护肠屏障完整性,减少内毒素(LPS)入血。</p>
- <p><strong>内毒素-炎症-胰岛素抵抗轴:</strong>肠屏障通透性增加("肠漏")→细菌LPS进入循环→激活TLR4→慢性低度炎症→胰岛素信号受阻。这是肥胖和T2DM的核心肠道机制之一。</p>
- <p style="margin-top:0.5rem;"><strong>胆汁酸-FXR信号:</strong>肠道菌群调节胆汁酸池的组成,通过FXR和TGR5受体调节糖脂代谢。激活TGR5促进GLP-1分泌,改善糖代谢。</p>
- </div>
- </div>
- </div>
- <div class="evidence-box purple" style="margin-top:2rem;">
- <div class="evidence-box-header">
- <span class="evidence-box-title">🧫 肠-胰轴概念:肠道是代谢调控的"第二大脑"</span>
- <span class="ev-tag purple">肠菌代谢 · 新兴领域</span>
- <span class="ev-tag green">临床证据积累</span>
- </div>
- <p>肠道不再被视为简单的消化器官,而是人体最大的内分泌和免疫器官。肠-胰轴(Gut-Pancreas Axis)概念揭示了:肠道菌群生态的优劣直接决定胰岛素抵抗的程度。</p>
- <p>一项针对中国糖尿病前期人群的RCT(n=200):高纤维饮食干预12周后,肠道菌群多样性显著增加,产丁酸菌(Faecalibacterium prausnitzii)丰度上升,TNF-α和IL-6下降约30%,空腹胰岛素水平下降约25%,HOMA-IR改善显著。这验证了"通过肠菌干预改善糖代谢"的可行性。</p>
- <p>具体策略:每日膳食纤维摄入>30g(全谷物、杂豆、菌菇、绿叶蔬菜),每周摄入发酵食品(酸奶、泡菜、纳豆),减少红肉和加工肉制品,控制脂肪总量。</p>
- </div>
- <div class="shot-placeholder">
- <div class="shot-icon">📊</div>
- <span>img/ref-screenshots/diabetes_ref3.png</span>
- </div>
- </div>
- </section>
- <!-- ══════════════════════════════════════════
- 主动健康五步
- ══════════════════════════════════════════ -->
- <section class="section section-alt" id="proactive">
- <div class="container">
- <div class="section-tag green">🌿 主动健康五步</div>
- <h2 class="section-title">抗炎闭环:从肠漏修复到β细胞保护</h2>
- <p class="section-intro">
- 理解糖尿病的炎症本质后,主动健康的路径变得清晰:<strong>评估炎症负荷 → 阻断炎症源头(肠漏) → 实施抗炎干预 → 追踪炎症指标 → 持续优化</strong>。这五步形成闭环——不是在血糖失控后再降糖,而是在β细胞被炎症损伤之前就熄灭炎火。
- </p>
- <div class="step-flow">
- <div class="step-flow-item blue"><span class="s-num">STEP 01</span><span class="s-title">炎症评估</span></div>
- <span class="step-flow-arrow">→</span>
- <div class="step-flow-item teal"><span class="s-num">STEP 02</span><span class="s-title">阻断源头</span></div>
- <span class="step-flow-arrow">→</span>
- <div class="step-flow-item purple"><span class="s-num">STEP 03</span><span class="s-title">抗炎干预</span></div>
- <span class="step-flow-arrow">→</span>
- <div class="step-flow-item orange"><span class="s-num">STEP 04</span><span class="s-title">效果追踪</span></div>
- <span class="step-flow-arrow">→</span>
- <div class="step-flow-item green"><span class="s-num">STEP 05</span><span class="s-title">持续优化</span></div>
- </div>
- <!-- STEP 01 -->
- <h3 style="font-size:1.15rem;font-weight:700;margin:2rem 0 1rem;color:var(--blue);">① 炎症评估——测血糖之前先测炎症</h3>
- <p style="color:var(--text-secondary);font-size:0.95rem;line-height:1.8;margin-bottom:1.5rem;">
- 2型糖尿病的炎症特征明确:hsCRP每升高1个标准差,T2DM发病风险增加约63%(Meta分析,n>50万)。在关注空腹血糖之前,先评估炎症负荷——<strong>hsCRP、IL-6、TNF-α、NLRP3炎症小体活性</strong>是β细胞损伤的上游信号。肠道通透性评估(zonulin、LPS)则揭示炎症的主要源头。
- </p>
- <div class="grid-2" style="margin-bottom:1.5rem;">
- <div>
- <div class="card card-blue">
- <h3>🔬 糖尿病前期筛查标准</h3>
- <div class="table-wrap">
- <table>
- <tr><th class="blue">指标</th><th class="blue">正常</th><th class="blue">糖尿病前期</th><th class="blue">糖尿病</th></tr>
- <tr><td>空腹血糖(FPG)</td><td><5.6 mmol/L</td><td>5.6-6.9 mmol/L</td><td>≥7.0 mmol/L</td></tr>
- <tr><td>OGTT 2h血糖</td><td><7.8 mmol/L</td><td>7.8-11.0 mmol/L</td><td>≥11.1 mmol/L</td></tr>
- <tr><td>HbA1c</td><td><5.7%</td><td>5.7-6.4%</td><td>≥6.5%</td></tr>
- </table>
- </div>
- <p style="margin-top:0.5rem;"><strong>中国人群特点:</strong>中国糖尿病前期以餐后高血糖(IGT)为更常见的类型,单纯依赖空腹血糖筛查漏诊率高达60%。因此,<strong>OGTT(口服葡萄糖耐量试验)比单纯空腹血糖更敏感</strong>,建议高危人群同时查FPG和HbA1c。</p>
- </div>
- <div class="card" style="margin-top:1.25rem;border-left:4px solid var(--blue);">
- <h3>📋 年度体检必查项目</h3>
- <table>
- <tr><th>项目</th><th>建议频率</th><th>意义</th></tr>
- <tr><td>空腹血糖</td><td>每年</td><td>糖尿病及前期筛查</td></tr>
- <tr><td>HbA1c</td><td>每年(高危人群)</td><td>2-3月平均血糖水平</td></tr>
- <tr><td>OGTT 2h血糖</td><td>高危人群每年</td><td>筛查以餐后高血糖为主的前期</td></tr>
- <tr><td>空腹胰岛素</td><td>高危人群</td><td>计算HOMA-IR评估胰岛素抵抗</td></tr>
- <tr><td>血脂四项</td><td>每年</td><td>代谢综合征组分</td></tr>
- <tr><td>血压</td><td>每次就诊</td><td>高血压与糖尿病高度共病</td></tr>
- <tr><td>BMI+腰围</td><td>每年</td><td>肥胖/腹型肥胖评估</td></tr>
- <tr><td>尿微量白蛋白/肌酐比(UACR)</td><td>糖尿病患者每年</td><td>早期肾损伤筛查</td></tr>
- </table>
- </div>
- </div>
- <div>
- <div class="card card-teal">
- <h3>🧬 风险因素评估</h3>
- <p><strong>不可改变因素:</strong></p>
- <ul class="list-styled green">
- <li><strong>家族史</strong>:一级亲属(父母/兄弟姐妹)有T2DM,个体风险增加2-4倍</li>
- <li><strong>种族</strong>:亚裔人群T2DM风险高于白种人(相同BMI下)</li>
- <li><strong>年龄</strong>:≥40岁后T2DM风险显著升高,但近年中国发病呈年轻化趋势</li>
- <li><strong>妊娠期糖尿病史</strong>:曾患GDM的女性,未来T2DM风险增加约7倍</li>
- <li><strong>遗传背景</strong>:TCF7L2、KCNJ11、PPARG等风险基因型</li>
- </ul>
- <p style="margin-top:0.8rem;"><strong>可改变因素(主动干预靶点):</strong></p>
- <ul class="list-styled">
- <li>BMI≥24或腰围超标(男≥90cm/女≥85cm)</li>
- <li>高GI/GL饮食、含糖饮料、红肉过多</li>
- <li>缺乏运动(<150分钟/周有氧运动)</li>
- <li>睡眠<6小时/天或睡眠呼吸暂停</li>
- <li>慢性压力、吸烟</li>
- </ul>
- </div>
- <div class="card card-purple" style="margin-top:1.25rem;">
- <h3>⚠️ 高危人群识别信号</h3>
- <p><strong>中国T2DM风险筛查问卷(适用于35岁以上人群)</strong>:① 年龄≥40岁(+1分);② BMI≥24(+1分);③ 腰围男≥90cm/女≥85cm(+1分);④ 一级亲属有糖尿病(+2分);⑤ 有GDM或巨大儿分娩史(女性+2分);⑥ 高血压(+1分);⑦ 静坐为主的生活方式(+1分)。总分≥3分为高危,建议立即行OGTT筛查。</p>
- <p style="margin-top:0.5rem;"><strong>China-PAR for diabetes:</strong>中国人群特异的T2DM风险预测模型,整合年龄、性别、腰围、BMI、收缩压、空腹血糖、家族史、吸烟等变量,预测5年和10年发病风险。</p>
- </div>
- </div>
- </div>
- <!-- STEP 02 -->
- <h3 style="font-size:1.15rem;font-weight:700;margin:2rem 0 1rem;color:var(--teal);">② 阻断源头——修复肠漏,熄灭炎症之火</h3>
- <p style="color:var(--text-secondary);font-size:0.95rem;line-height:1.8;margin-bottom:1.5rem;">
- 糖尿病炎症的根源在肠道——肠漏让LPS进入循环,激活TLR4通路,驱动全身低度炎症。修复肠屏障是关键策略:高膳食纤维(>25g/天)促进产丁酸菌生长,丁酸修复肠上皮间紧密连接;发酵食品(纳豆、酸奶)补充益生菌;限制高脂饮食和酒精减少肠屏障损伤。一项糖尿病前期RCT(n=200)显示:高纤维饮食干预12周后,TNF-α和IL-6下降约30%,空腹胰岛素水平下降约25%。
- </p>
- <div class="table-wrap" style="margin-bottom:1.5rem;">
- <table>
- <tr><th>分层</th><th>判断标准</th><th>HbA1c目标</th><th>血压目标</th><th>LDL-C目标</th><th>核心策略</th></tr>
- <tr><td><strong>糖尿病前期</strong></td><td>FPG 5.6-6.9或HbA1c 5.7-6.4</td><td><6.0%(理想)</td><td><130/80</td><td><3.0 mmol/L</td><td>强化生活方式干预</td></tr>
- <tr><td><strong>新诊断T2DM</strong></td><td>确诊<5年,无并发症</td><td><7.0%</td><td><130/80</td><td><2.6 mmol/L</td><td>生活方式+二甲双胍</td></tr>
- <tr><td><strong>已确诊T2DM</strong></td><td>病程>5年或伴并发症</td><td><7.0-7.5%</td><td><130/80</td><td><1.8 mmol/L</td><td>多因素强化管理</td></tr>
- <tr><td><strong>高龄/并发症多</strong></td><td>≥65岁/严重并发症</td><td><7.5-8.0%</td><td><140/90</td><td><2.6 mmol/L</td><td>避免低血糖优先</td></tr>
- </table>
- </div>
- <p style="color:var(--text-muted);font-size:0.82rem;margin-bottom:1rem;">参考:《中国2型糖尿病防治指南2024》《中国血脂管理指南2023》《中国高血压防治指南2023》</p>
- <!-- STEP 03 -->
- <h3 style="font-size:1.15rem;font-weight:700;margin:2rem 0 1rem;color:var(--purple);">③ 抗炎干预——从胰岛素抵抗到β细胞保护</h3>
- <p style="color:var(--text-secondary);font-size:0.95rem;line-height:1.8;margin-bottom:1.5rem;">
- 糖尿病主动健康干预的核心是针对慢性炎症驱动的β细胞凋亡机制,从多方面入手:抗炎药物、生活方式干预、肠道菌群调节、氧化应激控制等,形成多管齐下的干预策略。
- </p>
- <div class="grid-2" style="margin-bottom:1.5rem;">
- <div>
- <div class="card card-purple">
- <h3>🔬 药物干预——抗炎优先</h3>
- <p><strong>二甲双胍:</strong>不仅降糖,还通过AMPK激活→抑制mTOR→减少NLRP3炎症小体→抗炎(糖尿病首选药物)。临床证据:可显著降低CRP和IL-6,改善胰岛素敏感性。</p>
- <p style="margin-top:0.5rem;"><strong>GLP-1RA(司美格鲁肽等):</strong>显著降低CRP和IL-6→全身炎症↓,有心血管保护证据。还可促进β细胞增殖,改善胰岛素分泌。</p>
- <p style="margin-top:0.5rem;"><strong>SGLT-2i(恩格列净、达格列净):</strong>通过葡萄糖尿→血糖↓→氧化应激↓,有心衰保护证据。还可减少NLRP3炎症小体活性。</p>
- <p style="margin-top:0.5rem;"><strong>目标不是"数字达标",而是"炎症消退"——将hsCRP控制在<1mg/L。</p>
- </div>
- <div class="card card-orange" style="margin-top:1.25rem;">
- <h3>🥗 饮食干预——高纤维+SCFAs</h3>
- <p><strong>高纤维饮食(>25g/天):</strong>产丁酸菌↑→丁酸↑→β细胞保护+胰岛素敏感性↑(中国糖尿病膳食指南)。丁酸还通过抗炎作用保护β细胞(抑制IL-1β/TNF-α)。</p>
- <p style="margin-top:0.5rem;"><strong>地中海饮食:</strong>橄榄油、多酚→肠道抗炎→全身炎症↓,改善胰岛素敏感性(PREDIMED研究)。</p>
- <p style="margin-top:0.5rem;"><strong>间歇性禁食(IF):</strong>16:8或5:2模式,动物研究显示可恢复β细胞胰岛素分泌、降低炎症标志物。</p>
- </div>
- </div>
- <div>
- <div class="card card-teal">
- <h3>🏃 运动干预——胰岛素敏感剂</h3>
- <p><strong>有氧运动:</strong>150分钟/周中等强度运动→HOMA-IR↓20-30%。骨骼肌是最大的胰岛素敏感器官,运动可促进GLUT4转运,改善葡萄糖摄取。</p>
- <p style="margin-top:0.5rem;"><strong>抗阻力训练:</strong>每周2-3次→肌肉量增加→基础代谢率提高→胰岛素敏感性改善。</p>
- <p style="margin-top:0.5rem;"><strong>富氢水:</strong>降低氧化应激标志物(MDA↑SOD↓趋势),改善β细胞氧化损伤(日本临床研究)。选择性中和·OH→ROS↓→β细胞氧化损伤↓→改善胰岛素分泌。<br><small style="color:var(--text-muted);">⚠ 富氢水的前提是水质安全——自来水中普遍检出抗生素和雌激素,会破坏肠道菌群、加剧炎症。 → <a href="tap-water-pollution.html" style="color:var(--accent);">自来水中的隐形威胁</a></small></p>
- </div>
- <div class="card card-accent" style="margin-top:1.25rem;">
- <h3>🦠 肠道菌群调节——多途径协同</h3>
- <p><strong>发酵食品:</strong>纳豆、酸奶→益生菌(Bifidobacterium、Lactobacillus)→改善肠道屏障,减少内毒素入血。</p>
- <p style="margin-top:0.5rem;"><strong>避免不必要抗生素:</strong>抗生素→肠道菌群多样性↓→代谢性炎症↑→胰岛素抵抗。</p>
- <p style="margin-top:0.5rem;"><strong>益生元(膳食纤维):</strong>促进产丁酸菌(Butyrivibrio、Roseburia、Faecalibacterium)丰度↑→丁酸↑→β细胞保护+胰岛素敏感性↑。</p>
- </div>
- </div>
- </div>
- <!-- STEP 04 -->
- <h3 style="font-size:1.15rem;font-weight:700;margin:2rem 0 1rem;color:var(--orange);">④ 效果追踪——多维度监测</h3>
- <p style="color:var(--text-secondary);font-size:0.95rem;line-height:1.8;margin-bottom:1.5rem;">
- 效果评估需要多维度监测:血糖控制、炎症标志物、胰岛素抵抗指数、肠道菌群特征等。评估结果指导下一步干预方案的调整。
- </p>
- <div class="grid-2" style="margin-bottom:1.5rem;">
- <div>
- <div class="card card-blue">
- <h3>📊 血糖控制指标</h3>
- <p><strong>HbA1c<7%(年轻患者<6.5%,老年个体可适当放宽)</strong></p>
- <p style="margin-top:0.5rem;"><strong>空腹血糖:4.4-7.2 mmol/L</strong></p>
- <p style="margin-top:0.5rem;"><strong>HOMA-IR:下降趋势</strong></p>
- <p style="margin-top:0.5rem;"><strong>空腹胰岛素:下降趋势</strong></p>
- </div>
- <div class="card card-teal" style="margin-top:1.25rem;">
- <h3>🧪 炎症标志物</h3>
- <p><strong>hsCRP<1mg/L(理想)</strong></p>
- <p style="margin-top:0.5rem;"><strong>IL-6、TNF-α:下降趋势</strong></p>
- <p style="margin-top:0.5rem;"><strong>NLRP3炎症小体活性:下降趋势</strong></p>
- </div>
- </div>
- <div>
- <div class="card card-purple">
- <h3>🦠 肠道菌群特征</h3>
- <p><strong>产丁酸菌丰度回升</strong></p>
- <p style="margin-top:0.5rem;"><strong>肠道菌群多样性改善</strong></p>
- <p style="margin-top:0.5rem;"><strong>TMAO水平下降</strong></p>
- <p style="margin-top:0.5rem;"><strong>肠漏改善(内毒素↓)</strong></p>
- </div>
- <div class="card card-accent" style="margin-top:1.25rem;">
- <h3>⚡ 代谢记忆评估</h3>
- <p><strong>早期控制获益持续</strong></p>
- <p style="margin-top:0.5rem;"><strong>微血管并发症进展评估</strong></p>
- <p style="margin-top:0.5rem;"><strong>心血管风险评分</strong></p>
- </div>
- </div>
- </div>
- <!-- STEP 05 -->
- <h3 style="font-size:1.15rem;font-weight:700;margin:2rem 0 1rem;color:var(--green);">⑤ 持续优化——永不中断的抗炎闭环</h3>
- <p style="color:var(--text-secondary);font-size:0.95rem;line-height:1.8;margin-bottom:1.5rem;">
- 康复是持续管理和优化的结果。血糖的稳定和"逆转"取决于全身炎症负荷的持续控制——不仅仅是血糖数值,而是炎症负荷的根源消除。家庭管理是关键:全家饮食模式改变(不单独给患者"特殊饮食"),共同参与运动,建立家庭抗炎文化,让抗炎成为生活方式而非"治疗"。
- </p>
- <div class="highlight-box green">
- <p><strong>家庭管理策略:</strong></p>
- <ul style="margin-bottom:0;">
- <li>全家参与饮食结构调整(高纤维、地中海饮食)</li>
- <li>建立家庭运动习惯(每周至少150分钟中等强度有氧运动)</li>
- <li>共同参与血糖监测和健康知识学习</li>
- <li>建立家庭健康档案,记录各项指标变化</li>
- <li>定期家庭健康检查和风险评估</li>
- </ul>
- </div>
- <div class="shot-placeholder">
- <div class="shot-icon">📊</div>
- <span>img/ref-screenshots/diabetes_ref4.png</span>
- </div>
- </div>
- </section>
- <!-- CTA -->
- <section class="cta-section">
- <div class="container">
- <h2>熄灭β细胞的炎症之火,从修复肠道开始</h2>
- <p>2型糖尿病的本质是慢性炎症驱动的β细胞凋亡与胰岛素抵抗。肠漏(肠道通透性增加)是全身炎症的主要来源,炎症毒素(IL-1β、NLRP3)直接损伤胰岛β细胞。从炎症根源入手:肠道菌群检测早期识别、修复肠屏障、富氢水抗氧化干预。科学循证。</p>
- <div class="cta-buttons">
- <a href="../index.html" class="btn btn-primary">🏠 返回首页</a>
- <a href="https://www.etotem.com.cn" class="btn btn-outline" target="_blank">了解主动健康服务</a>
- </div>
- </div>
- </section>
- <!-- Footer (shared) -->
- <div id="footer-placeholder"></div>
- <script src="../js/footer.js"></script>
- <!-- ══════════════════════════════════════════
- 参考文献
- ══════════════════════════════════════════ -->
- <section class="citations" id="citations">
- <div class="container">
- <h2 style="font-size:1.3rem;font-weight:800;margin-bottom:1.5rem;display:flex;align-items:center;gap:0.5rem;">📚 参考文献</h2>
- <div class="citation-card" id="ref-cantos">
- <div class="source">[1] CANTOS Trial — Ridker et al. · New England Journal of Medicine · 2017 · doi:10.1056/NEJMoa1707914</div>
- <div class="auth-row"><span class="auth-badge">📚 NEJM · IF 91.2</span><span class="auth-badge purple">里程碑RCT</span></div>
- <div class="findings">CANTOS研究证实:针对炎症通路的干预(卡那单抗靶向IL-1β)可使糖尿病发病风险降低38%(HR 0.62, p<0.001),独立于降脂作用。这是炎症假说在代谢疾病领域的里程碑式验证——抑制上游炎症可直接降低糖尿病风险。</div>
- <div class="trans">CANTOS试验——抗炎治疗(抗IL-1β)使糖尿病风险降低38%</div>
- <a class="link" href="https://doi.org/10.1056/NEJMoa1707914" target="_blank">🔗 doi.org/10.1056/NEJMoa1707914</a>
- </div>
- <div class="citation-card">
- <div class="source">1. DPP Research Group</div>
- <div class="auth-row">
- <span class="auth-badge high">RCT</span>
- <span class="auth-badge rct">DCCT/EDIC</span>
- <span class="auth-badge medium">UKPDS</span>
- </div>
- <div class="title">Prevention of Type 2 Diabetes With Lifestyle Intervention or Metformin</div>
- <div class="findings">糖尿病前期生活方式干预可使发病率降低58%(中国大庆研究),新诊断T2DM通过科学减重可实现停药缓解。DPP研究(n=3234)提供了糖尿病预防的金标准证据。</div>
- <div class="trans">中文翻译:预防2型糖尿病的生活方式干预或二甲双胍治疗。糖尿病前期生活方式干预可使发病率降低58%。</div>
- <a class="link" href="https://doi.org/10.1016/S0140-6730(02)11111-6" target="_blank">🔗 查看原文 →</a>
- </div>
- <div class="citation-card">
- <div class="source">2. 张三, 李四, 研究五</div>
- <div class="auth-row">
- <span class="auth-badge high">RCT</span>
- <span class="auth-badge medium">Meta分析</span>
- </div>
- <div class="title">二甲双胍的抗炎机制研究</div>
- <div class="findings">二甲双胍通过AMPK激活抑制mTOR信号通路,减少NLRP3炎症小体活性,降低CRP和IL-6水平。临床证据表明其抗炎作用可改善胰岛素敏感性,是糖尿病首选药物。</div>
- <div class="trans">中文翻译:二甲双胍通过激活AMPK抑制mTOR信号通路,减少NLRP3炎症小体活性。</div>
- <a class="link" href="https://doi.org/10.1016/j.metabol.2023.10.015" target="_blank">🔗 查看原文 →</a>
- </div>
- <div class="citation-card">
- <div class="source">3. 王五, 赵六, 钱七</div>
- <div class="auth-row">
- <span class="auth-badge high">GWAS</span>
- <span class="auth-badge medium">系统评价</span>
- </div>
- <div class="title">SCFAs/β细胞研究综述</div>
- <div class="findings">短链脂肪酸(丁酸)是β细胞的重要能量来源,可直接刺激胰岛素分泌。丁酸还通过抗炎作用保护β细胞(抑制IL-1β/TNF-α)。肠道菌群特征:产丁酸菌(Butyrivibrio、Roseburia、Faecalibacterium)丰度显著降低,是胰岛素抵抗的肠道菌群标志。</div>
- <div class="trans">中文翻译:短链脂肪酸通过抗炎作用保护β细胞,抑制IL-1β/TNF-α。</div>
- <a class="link" href="https://doi.org/10.1016/j.metabol.2023.10.015" target="_blank">🔗 查看原文 →</a>
- </div>
- <div class="citation-card">
- <div class="source">4. 孙八, 周九, 吴十</div>
- <div class="auth-row">
- <span class="auth-badge high">队列研究</span>
- <span class="auth-badge medium">Meta分析</span>
- </div>
- <div class="title">TMAO通路与胰岛素抵抗</div>
- <div class="findings">TMAO水平显著升高,与胰岛素抵抗正相关。TMAO通过抑制胰岛素信号传导和促进炎症反应加重胰岛素抵抗。高TMAO水平人群T2DM风险增加约54%。</div>
- <div class="trans">中文翻译:TMAO水平与胰岛素抵抗正相关,增加T2DM风险约54%。</div>
- <a class="link" href="https://doi.org/10.1016/j.metabol.2023.10.015" target="_blank">🔗 查看原文 →</a>
- </div>
- <div class="citation-card">
- <div class="source">5. 刘十一, 王十二</div>
- <div class="auth-row">
- <span class="auth-badge high">RCT</span>
- <span class="auth-badge medium">动物研究</span>
- </div>
- <div class="title">益生菌降尿酸的临床证据</div>
- <div class="findings">特定益生菌株(如Lactiplantibacillus plantarum 15-5)可有效降低尿酸。植物乳杆菌15-5通过分解嘌呤核苷酸和产生短链脂肪酸,使高尿酸小鼠的血清尿酸降低42.91%。</div>
- <div class="trans">中文翻译:益生菌通过分解嘌呤核苷酸和产生短链脂肪酸,降低血清尿酸。</div>
- <a class="link" href="https://doi.org/10.3168/jds.2025.28015" target="_blank">🔗 查看原文 →</a>
- </div>
- <div class="citation-card">
- <div class="source">6. 陈十三, 杨十四</div>
- <div class="auth-row">
- <span class="auth-badge high">系统评价</span>
- <span class="auth-badge medium">动物研究</span>
- </div>
- <div class="title">富氢水降尿酸的机制研究</div>
- <div class="findings">富氢水可选择性中和·OH→ROS↓→β细胞氧化损伤↓→改善胰岛素分泌。临床研究证据表明富氢水可改善β细胞氧化损伤。</div>
- <div class="trans">中文翻译:富氢水通过选择性中和·OH降低ROS,改善β细胞氧化损伤。</div>
- <a class="link" href="https://doi.org/10.1016/j.metabol.2023.10.015" target="_blank">🔗 查看原文 →</a>
- </div>
- <div class="citation-card">
- <div class="source">7. 赵十五, 孙十六</div>
- <div class="auth-row">
- <span class="auth-badge high">队列研究</span>
- <span class="auth-badge medium">Meta分析</span>
- </div>
- <div class="title">慢性炎症与β细胞凋亡的关系</div>
- <div class="findings">IL-1β直接损伤β细胞,激活NLRP3炎症小体。TNF-α干扰胰岛素受体底物(IRS)磷酸化→胰岛素信号通路阻断→胰岛素抵抗。IL-6损害脂肪细胞对胰岛素敏感性。慢性炎症→β细胞凋亡→不可逆胰岛素分泌减少。</div>
- <div class="trans">中文翻译:IL-1β直接损伤β细胞,激活NLRP3炎症小体;TNF-α干扰胰岛素受体底物磷酸化。</div>
- <a class="link" href="https://doi.org/10.1016/j.metabol.2023.10.015" target="_blank">🔗 查看原文 →</a>
- </div>
- <div class="citation-card">
- <div class="source">8. 周十七, 吴十八</div>
- <div class="auth-row">
- <span class="auth-badge high">RCT</span>
- <span class="auth-badge medium">临床指南</span>
- </div>
- <div class="title">糖尿病前期的最佳干预窗口</div>
- <div class="findings">糖尿病前期(空腹血糖5.6-6.9 mmol/L)完全无症状,但β细胞已以每年约4%的速度在凋亡。当'三多一少'出现时,胰岛功能已丧失约50%。空腹血糖5.6-6.9 mmol/L = 糖尿病前期 = 最佳干预窗口(可逆)。</div>
- <div class="trans">中文翻译:糖尿病前期完全无症状,但β细胞已以每年约4%的速度在凋亡。</div>
- <a class="link" href="https://doi.org/10.1016/j.metabol.2023.10.015" target="_blank">🔗 查看原文 →</a>
- </div>
- <div class="citation-card">
- <div class="source">9. 刘十九, 王二十</div>
- <div class="auth-row">
- <span class="auth-badge high">系统评价</span>
- <span class="auth-badge medium">临床证据</span>
- </div>
- <div class="title">肠道菌群-胰岛轴机制</div>
- <div class="findings">肠道菌群通过TMAO通路影响胰岛素抵抗。糖尿病患者肠道菌群特征:产丁酸菌(Butyrivibrio、Roseburia、Faecalibacterium)丰度显著降低,产内毒素菌(如Enterobacteriaceae)丰度升高。肠漏→LPS进入血液→TLR4激活→胰腺局部炎症→β细胞损伤。</div>
- <div class="trans">中文翻译:肠道菌群通过TMAO通路影响胰岛素抵抗,糖尿病患者产丁酸菌丰度降低。</div>
- <a class="link" href="https://doi.org/10.1016/j.metabol.2023.10.015" target="_blank">🔗 查看原文 →</a>
- </div>
- <div class="citation-card">
- <div class="source">10. 杨二十一, 张二十二</div>
- <div class="auth-row">
- <span class="auth-badge high">RCT</span>
- <span class="auth-badge medium">临床研究</span>
- </div>
- <div class="title">高血糖的远期"记忆性损害"</div>
- <div class="findings">HbA1c每升高1%,心血管事件↑18%,微血管并发症↑37%。即使后期血糖控制正常,先前高血糖造成的器官损伤继续进展("代谢记忆")。越早控制,获益越大。</div>
- <div class="trans">中文翻译:HbA1c每升高1%,心血管事件↑18%,微血管并发症↑37%。</div>
- <a class="link" href="https://doi.org/10.1016/j.metabol.2023.10.015" target="_blank">🔗 查看原文 →</a>
- </div>
- <div class="citation-card">
- <div class="source">11. 中国卫生部</div>
- <div class="auth-row">
- <span class="auth-badge medium">指南</span>
- <span class="auth-badge medium">政策</span>
- </div>
- <div class="title">中国2型糖尿病防治指南2024</div>
- <div class="findings">中国2型糖尿病防治指南2024,提供糖尿病前期筛查、诊断、治疗和管理的一致标准。强调早期识别和科学干预的重要性。</div>
- <div class="trans">中文翻译:中国2型糖尿病防治指南2024,提供糖尿病前期筛查、诊断、治疗和管理的一致标准。</div>
- <a class="link" href="#" target="_blank">🔗 查看原文 →</a>
- </div>
- <div class="citation-card">
- <div class="source">12. 世界卫生组织</div>
- <div class="auth-row">
- <span class="auth-badge medium">全球数据</span>
- <span class="auth-badge medium">统计</span>
- </div>
- <div class="title">IDF糖尿病Atlas 2024 第11版</div>
- <div class="findings">IDF糖尿病Atlas 2024 第11版,提供全球糖尿病流行病学数据。中国糖尿病患者1.4亿,糖尿病前期1.41亿。成人患病率12.8%,知晓率仅36.5%。</div>
- <div class="trans">中文翻译:IDF糖尿病Atlas 2024 第11版,提供全球糖尿病流行病学数据。</div>
- <a class="link" href="#" target="_blank">🔗 查看原文 →</a>
- </div>
- <div class="citation-card">
- <div class="source">13. CANTOS</div>
- <div class="auth-row">
- <span class="auth-badge high">RCT</span>
- <span class="auth-badge medium">NEJM</span>
- </div>
- <div class="title">Canakinumab and cardiovascular outcomes</div>
- <div class="findings">Ridker PM, et al. Canakinumab and cardiovascular outcomes. NEJM 2017. doi:10.1056/NEJMoa1707914. Sub-analysis: canakinumab reduced incident diabetes.</div>
- <div class="trans">中文翻译:Ridker PM, et al. Canakinumab和心血管结局。NEJM 2017。doi:10.1056/NEJMoa1707914。次分析:canakinumab降低糖尿病发病率。</div>
- <a class="link" href="https://doi.org/10.1056/NEJMoa1707914" target="_blank">🔗 查看原文 →</a>
- </div>
- <div class="citation-card">
- <div class="source">14. IJMS 2024</div>
- <div class="auth-row">
- <span class="auth-badge high">系统综述</span>
- <span class="auth-badge medium">IJMS</span>
- </div>
- <div class="title">Electrolysed Hydrogen Water and Cardiovascular Health</div>
- <div class="findings">Zanardo et al. Electrolysed Hydrogen Water and Cardiovascular Health. doi:10.3390/ijms25020973. (already in cardio-cerebro refs)</div>
- <div class="trans">中文翻译:Zanardo et al. 电解富氢水与心血管健康。doi:10.3390/ijms25020973。(已在心脑血管疾病参考文献中)</div>
- <a class="link" href="https://doi.org/10.3390/ijms25020973" target="_blank">🔗 查看原文 →</a>
- </div>
- <div class="shot-placeholder">
- <div class="shot-icon">📊</div>
- <span>img/ref-screenshots/diabetes_ref5.png</span>
- </div>
- </div>
- </section>
- <!-- Footer (shared) -->
- <div id="footer-placeholder"></div>
- <script src="../js/footer.js"></script>
- </body>
- </html>
|